Insmed Incorporated

Insmed is a biotechnology company that develops medicines for rare and serious lung diseases and genetic disorders. The company's main approved product is ARIKAYCE, a treatment for a difficult-to-treat type of lung infection. Insmed is also testing several other drugs in clinical trials, including treatments for bronchiectasis (a disease that damages the airways), pulmonary hypertension (high blood pressure in the lungs), and Duchenne muscular dystrophy (a genetic muscle-wasting disease). The company is headquartered in New Jersey.